arrow
Y

Yousuf Razvi

university college london
H指数:25
被引数:2,627

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Monoclonal gammopathy exclusion in transthyretin amyloid cardiomyopathy: iStopMM estimated glomerular filtration rate-adjusted serum-free light chain ratio cut-offs

在转甲状腺素蛋白淀粉样变性心肌病中排除单克隆丙种球蛋白病:iStopMM估算的肾小球滤过率校正的血清游离轻链比率阈值

2026-04-070
OA
Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm

心房机械收缩预测转甲状腺素蛋白淀粉样变性心肌病合并窦性心律患者的脑血管风险

JACC
IF0
2026-02-180
OAAI
Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis

修订后的肾分层和进展模型,用于预测免疫球蛋白轻链淀粉样变性患者的长期肾脏结局

2025-12-012
OAAI
Myocardial Amyloid Burden in Transthyretin Amyloidosis

转甲状腺素蛋白淀粉样变性中的心肌淀粉样蛋白负荷

JACC
IF0
2025-11-080
OAAI
Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis

基于人工智能的心脏超声评估在监测甲状腺素转运蛋白心脏淀粉样变性疾病进展中的应用

2025-10-160
OAAI
Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy

治疗后转甲状腺素蛋白淀粉样变性心肌病中连续骨闪烁显像结果的临床相关性不确定

2025-07-090
OAAI
Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance

Patel, R.K.; Ioannou, A.; Sheikh, A.; Razvi, Y.; Mansell, J.; Martinez-Naharro, A.; Knight, D.; Kotecha, T.; Porcari, A.; Chacko, L.; 等. 甲状腺素转运蛋白淀粉样变性心肌病:基于心血管磁共振的自然病程及治疗反应评估。Eur. Heart J. 2025, ehaf412. [Google Scholar] [CrossRef] [PubMed]

2025-07-014
OAAI
Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis

转甲状腺素蛋白心脏淀粉样变性中虚弱症的临床表型与预后意义

2025-04-011
OAAI
Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid Infiltration

无症状型转甲状腺素蛋白心脏淀粉样变性患者的临床表型与预后

2025-01-221
PRE
Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy
2025-01-010
OA
Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy
2024-12-010
PRE
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis
2024-11-010
OAAI
Microvascular obstruction in cardiac amyloidosis

心脏淀粉样变性的微血管阻塞

2024-10-180
OA